Join The Conversation Card Front 01 Copy

The Medtechy Daily: November 15, 2018

Posted on November 15, 2018 by Medtech[y] Staff

The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health.

Tweet of the Day


AliveCor's Next App Could Save You From a Heart Attack. AliveCor, maker of ECG software and hardware for the iPhone and other mobile devices, received another impressive victory this week as an international study found that their smartphone app was nearly as accurate as a 12-lead ECG in determining if a patient is having an ST-segment elevation myocardial infarction (STEMI). (Medtechy)

Alcon files initial Form 20-F registration statement with SEC for proposed spinoff. Novartis today announced that Alcon has filed an initial Form 20-F registration statement with the US Securities and Exchange Commission (SEC) in relation to the previously-announced intention of Novartis to spin off its eye care division as an independent, publicly-traded company. (Medtechy)

Stereotaxis Reports 4% Recurring Growth with System Revenue Down Over 50%. Stereotaxis (OTCQX: STXS), reported financial results for the third quarter, showing overall recurring growth of 4% versus the prior year quarter and a reduction in system revenue by over 50%. (Medtechy)

Axonics Hopes to Surpass Medtronic in Sacral Neuromodulation Market. Axonics’ CEO Raymond Cohen wants to have the top spot in the sacral neuromodulation market when it comes to treating patients with urinary and fecal dysfunction. But to reach this position, Axonics is going to have some pretty stiff competition from one of the largest players in the game – Medtronic. (MDDI)

Abbott wins CE Mark, FDA nod for DRG Invisible Trial neuromod system. Abbott (NYSE:ABT) said today that it won FDA clearance and CE Mark approval in the European Union for its DRG Invisible Trial System intended to allow patients with complex chronic pain conditions to receive a trial treatment with the company’s dorsal root ganglion stimulation system. (MassDevice)

AbbVie's Orilissa makes its uterine fibroids case with double phase 3 win. On Wednesday, the Illinois drugmaker and partner Neurocrine Biosciences unveiled details from a pair of phase 3 studies showing that the drug—already approved as a treatment for endometriosis-related pain—had topped placebo at reducing heavy menstrual bleeding related to uterine fibroids. (FiercePharma)